Bela M.
- Country
- Slovakia
- Department
- Department of Oncology
Research Overview
- Phase III Randomized Double-Blind Study of Alpelisib and Fulvestrant in HR-Positive, HER2-Negative Advanced Breast Cancer with PIK3CA Mutation
- A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPa
Data & Insights
Has run more than one trial at 10 of 135 partner sites.
Specializations
Breast Cancer Research
The investigator specializes in treating hormone receptor-positive (HR+), HER2-negative advanced breast cancer, exploring innovative therapeutic approaches for patients who have undergone various treatment lines.
- Advanced/Metastatic Disease Management
- Endocrine Therapy Combinations
- Novel Therapeutic Agents
Their research encompasses targeted therapies including CDK4/6 inhibitors and investigational compounds in combination with established treatments.
Additional Oncology Focus
The investigator's expertise extends to multiple solid tumor types, with particular attention to advanced malignancies including:
- Non-Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Liposarcoma
Their work includes evaluation of treatments for tumors with specific genetic alterations, particularly those involving CDK4 and CCND1 amplification.
Prostate Cancer Studies
The investigator conducts research in advanced prostate cancer treatment, with specific focus on:
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Novel Combination Approaches
- Treatment-Resistant Disease
Their work includes investigating innovative therapeutic combinations with established prostate cancer treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.